Reimbursed Care Access in Samoa

Currently classified as a strictly controlled substance under Samoa’s narcotics framework, with no authorized medical use outside of approved clinical research. The Narcotics Act and associated listings identify psilocybin/psilocin among prohibited substances. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA appears on lists of psychotropic substances controlled under Samoa’s narcotics regime. #

Esketamine (the S‑enantiomer formulation marketed internationally for treatment‑resistant depression) is not documented as an approved, reimbursed product in Samoa’s public medicine listings and there is no public record of national regulatory approval or a funded reimbursement pathway. Samoa’s medicines and health regime recognises ‘‘anaesthetic’’ and ‘‘drug/medicine’’ definitions within its Food and Drugs statutes, but those instruments do not constitute evidence that an imported proprietary esketamine product (e.g., Spravato®) has been authorised or reimbursed for psychiatric indications in Samoa. If esketamine were to be used it would require specific regulatory approval / import authorisation or participation in an authorised clinical trial. #

Ketamine is an established anaesthetic/analgesic agent that is regulated as a medicine under Samoa’s medicines/food statutes and is used in clinical settings for anesthesia and emergency care rather than as a reimbursed psychiatric psychedelic product. Samoa’s Food and Drugs legislation frames regulation of anaesthetics and new drugs under the Ministry of Health’s remit; regional reporting on Pacific Island health systems also notes the emergence/use of ketamine in clinical and non‑medical contexts, indicating ketamine is present in Pacific medical practice but without a documented national reimbursement program for ketamine‑assisted psychotherapy or an esketamine‑style labelled psychiatric indication. Any off‑label psychiatric use would be at the discretion of licensed clinicians and subject to importation/registration rules. #; #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT is explicitly listed among controlled psychotropic substances in public compilations of Samoa’s narcotics listings. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT and related tryptamines fall within the class of substances identified as controlled by Samoa’s narcotics framework. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine is included among substances flagged in listing extracts for the Samoa narcotics framework. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Components of ayahuasca preparations (notably DMT) are controlled under Samoa’s narcotics provisions, and there is no authorised traditional‑religious exemption or regulated clinical program publicly documented. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline is specifically identified in Samoa’s controlled‑substance listings. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Phenethylamine/2C series substances are encompassed by the broad class of controlled psychotropic substances referenced in Samoa’s narcotics materials and law‑reform commentary. #; #